We stated that this represents our intended cadence for updating the efficiency adjustment (3 years), plus an additional 2 years, since it has historically taken about 2 years to make changes to PFS valuation after we receive new recommendations from the RUC
Ghrelin Mimetic Pathway Understanding the two receptor systems clarifies why this stack delivers superior results
This work was supported by the Wilmot Cancer Institute Predoctoral Fellowship (to G.A.), the American Association for Cancer Research and Breast Cancer Research Foundation (20-20-26-HARR to I.S.H.), the Breast Cancer Coalition of Rochester (to I.S.H.), the American Cancer Society (RSG-23-971782-01-TBE to I.S.H.), the Ludwig Center for Metastasis Research (to A.M.), the University of Chicago Comprehensive Cancer Center (to A.M.), the Cancer Research Foundation (to A.M.), the V Foundation (to A.M.), the Pancreatic Cancer Action Network (to G.C.), the Lung Cancer Research Foundation (to J.C.), and NIH grants R01CA269813 (to I.S.H.), R01CA269813-S1 (to M.Z.), R37CA230042 (to G.M.D.), R24AA022057 (to V.V.), R01AA028859 (to Y.C.), R01CA276461 (to A.M.), T32CA009594 and F31CA278362 (to C.S.), and AI150698 (to J.M.)
Answer: ULT should be offered to patients with recurrent flares, CKD stage 35, diuretic use, tophi, or chronic gout, and discussed early even after a first flare